Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Barrett-Lee

Showing results (31-40 of 40) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 40 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 2, 2007
Human epidermal growth factor receptor 2 status correlates with lymph node involvement in patients with estrogen receptor (ER) negative, but with grade in those with ER-positive early-stage breast cancer suitable for cytotoxic chemotherapyJohn M S Bartlett, Ian O Ellis, Mitch Dowsett, et al.
Journal of the National Cancer Institute|July 22, 2004
Conventional adjuvant chemotherapy versus single-cycle, autograft-supported, high-dose, late-intensification chemotherapy in high-risk breast cancer patients: a randomized trialRobert C F Leonard, Michael Lind, Christopher Twelves, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 25, 2018
Acquired Resistance of ER-Positive Breast Cancer to Endocrine Treatment Confers an Adaptive Sensitivity to TRAIL through Posttranslational Downregulation of c-FLIPLuke Piggott, Andreia Silva, Timothy Robinson, et al.
The Lancet. Oncology|November 5, 2023
Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer (UK TACT2; CRUK/05/19): quality of life results from a multicentre, phase 3, open-label, randomised, controlled trialGalina Velikova, James P Morden, Joanne S Haviland, et al.
Health Technology Assessment (Winchester, England)|May 12, 2026
Mammographic surveillance in breast cancer patients aged 50 years or older: a synopsis of the Mammo-50 RCTJanet Dunn, Peter Donnelly, Andrea Marshall, et al.
Breast Cancer Research and Treatment|March 1, 2023
Aromatase inhibition plus/minus Src inhibitor saracatinib (AZD0530) in advanced breast cancer therapy (ARISTACAT): a randomised phase II studyAilsa J Oswald, Stefan N Symeonides, Duncan Wheatley, et al.
Lancet (London, England)|May 19, 2009
Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trialPaul Ellis, Peter Barrett-Lee, Lindsay Johnson, et al.
The Lancet. Oncology|June 11, 2017
Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trialDavid Cameron, James P Morden, Peter Canney, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 15, 2020
Ten-Year Results of FAST: A Randomized Controlled Trial of 5-Fraction Whole-Breast Radiotherapy for Early Breast CancerAdrian Murray Brunt, Joanne S Haviland, Mark Sydenham, et al.
Nature Medicine|May 2, 2018
Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT TrialAndrew Tutt, Holly Tovey, Maggie Chon U Cheang, et al.
Pageof 4

Showing results (31-40 of 40) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 40 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 2, 2007
Human epidermal growth factor receptor 2 status correlates with lymph node involvement in patients with estrogen receptor (ER) negative, but with grade in those with ER-positive early-stage breast cancer suitable for cytotoxic chemotherapyJohn M S Bartlett, Ian O Ellis, Mitch Dowsett, et al.
Journal of the National Cancer Institute|July 22, 2004
Conventional adjuvant chemotherapy versus single-cycle, autograft-supported, high-dose, late-intensification chemotherapy in high-risk breast cancer patients: a randomized trialRobert C F Leonard, Michael Lind, Christopher Twelves, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 25, 2018
Acquired Resistance of ER-Positive Breast Cancer to Endocrine Treatment Confers an Adaptive Sensitivity to TRAIL through Posttranslational Downregulation of c-FLIPLuke Piggott, Andreia Silva, Timothy Robinson, et al.
The Lancet. Oncology|November 5, 2023
Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer (UK TACT2; CRUK/05/19): quality of life results from a multicentre, phase 3, open-label, randomised, controlled trialGalina Velikova, James P Morden, Joanne S Haviland, et al.
Health Technology Assessment (Winchester, England)|May 12, 2026
Mammographic surveillance in breast cancer patients aged 50 years or older: a synopsis of the Mammo-50 RCTJanet Dunn, Peter Donnelly, Andrea Marshall, et al.
Breast Cancer Research and Treatment|March 1, 2023
Aromatase inhibition plus/minus Src inhibitor saracatinib (AZD0530) in advanced breast cancer therapy (ARISTACAT): a randomised phase II studyAilsa J Oswald, Stefan N Symeonides, Duncan Wheatley, et al.
Lancet (London, England)|May 19, 2009
Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trialPaul Ellis, Peter Barrett-Lee, Lindsay Johnson, et al.
The Lancet. Oncology|June 11, 2017
Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trialDavid Cameron, James P Morden, Peter Canney, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 15, 2020
Ten-Year Results of FAST: A Randomized Controlled Trial of 5-Fraction Whole-Breast Radiotherapy for Early Breast CancerAdrian Murray Brunt, Joanne S Haviland, Mark Sydenham, et al.
Nature Medicine|May 2, 2018
Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT TrialAndrew Tutt, Holly Tovey, Maggie Chon U Cheang, et al.
Pageof 4